FibroGen
Mark Lonergan has extensive experience in the manufacturing and supply operations field. Mark began their career in 1993 as a Project Leader at Genencor International, where they worked until 2001. In 2001, they joined FibroGen, Inc. as the Director of Contract Manufacturing. Over the years, they progressed through various roles, including Senior Director of Contract Manufacturing and Executive Director of Contract Manufacturing. Currently, they hold the position of Vice President, Manufacturing and Supply Operations at FibroGen, Inc.
Mark Lonergan completed their Bachelor of Science degree in Life Sciences II - Microbiology at Trinity College Dublin from 1987 to 1991. Following this, they pursued a Higher Diploma in Computer Science at University College Cork from 1991 to 1992. Later, Mark earned an MBA with a specialization in Finance from San Francisco State University, completing their studies between 2000 and 2006.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.